women <34 years were excluded since it was the first screening round in their life.
Findings: PCIN2/PCIN3 yields of HPV self-sampling responders were higher than those of screening participants (PCIN2: relative risk (RR) = 1.6, 95% confidence interval = 1.4-1.9; PCIN3: RR = 1.8, 95% CI = 1.5-2.1 with relative risk values increasing with age (test of homogeneity: PCIN2: p = 0.04; PCIN3: p = 0.03).
Native Dutch non-attendees responded better than immigrants (32% versus 22%, p < 0AE001) and those screened in the previous round revealed a higher response than underscreened (i.e. previous smear taken >7 years ago) or never screened (34% versus 25%, p < 0AE001) women. Strikingly, amongst under-and never screened women aged P39 years, never screened women responded better (25% versus 23%, p < 0AE001). PCIN2 rates were higher amongst responding native Dutch women than immigrants (p < 0AE01), and higher in under-/never screened women than in women screened in the previous round (p < 0AE01).
Interpretation: Offering hrHPV self-sampling increases the efficacy of the screening programme by targeting a substantial portion of non-attendees of all ethnic groups who have not regularly been screened and are at highest risk of PCIN2. 
Introduction
Organised cervical screening programmes have reduced the incidence of and mortality from cervical cancer. [1] [2] [3] Non-or infrequent attendance is one of the main threats to the success of those screening programmes. 4 Targeting non-attendees is important because these women have an increased risk of cervical cancer. 5 Recently, we found that offering self-sampling for high-risk HPV (hrHPV) testing (further referred to as HPV self-sampling) to non-attendees is an effective approach for increasing screening coverage (PROHTECT studies). 6, 7 Nevertheless, it is still unknown which subpopulations of non-attendees, in terms of age, ethnicity and screening history, are targeted by HPV self-sampling. It is known that screening participation rates vary across ethnic populations. 8 Moreover, not being screened within previous screening intervals has been found to be associated with increased risks of cervical intraepithelial neoplasia (CIN) grades 2 and 3, and cervical cancer. 6, [9] [10] [11] [12] Here, we used the pooled data from the two consecutive PROHTECT HPV self-sampling studies comprising a total of 52,447 non-attendees of the regular screening programme recruited from 230,509 women invited for cervical screening in the counties Noord-Holland and Flevoland in 2005 and 2006. First, we compared the yield of CIN2 or worse (PCIN2) and CIN3 or worse (PCIN3) of HPV self-sampling responders (n = 15,274) with that of their counterparts participating in primary cytology-based screening (n = 176,027). In addition, we analysed which subpopulations amongst non-attendees are targeted by HPV self-sampling, and how these characteristics relate to hrHPV prevalence and yield of PCIN2 and PCIN3. -Screener, Delphi-bioscience, The Netherlands) was offered to 27,792 women (self-sampling group), and a second recall for conventional cytology was sent to another 281 women (recall control group). 6 In (non-attendees in 2006) a brush-based self-sampling device (VibaBrush â , Rovers Medical Devices, The Netherlands) was offered to 26,145 women, whereas 264 women received a second recall for cytology. 7 Further study details have been described before. 6, 13, 14 Apart from the self-sampling method, both PROHTECT studies were essentially the same in design. Women with a hrHPV-positive self-sample were advised to visit a general practitioner for a cervical smear and referred for colposcopy in case of abnormal cytology (threshold borderline or mild dyskaryosis (BMD), equalling AGC/ASC-US/ASC-H/LSIL). Those with normal cytology received a re-invitation for a cervical scrape after 1 year, and were referred for colposcopy if either hrHPV test result was positive or cytology was abnormal. Women of the recall control groups were managed according to the current cytology guidelines of the national screening programme. 15 For the purpose of this study data from these PROHTECT studies were pooled.
Screening participants
The pooled 18 month yields of PCIN2/PCIN3 in the HPV sampling group were compared with those of all women (n = 176,027) who did participate in the regular screening programme in the same region and the same period. These women were managed according to the current cytology screening guidelines. 15 Cytology and histology results of both the HPV sampling group and the screening participants were obtained by querying the nationwide, centralised network and registry of histology and cytology database (PALGA; Bunnik, The Netherlands 16 ) as well as record tracking of individual cases of invited non-attendees. We linked patient records based on identity of the encrypted first four letters of the maiden name and date of birth. Groups of records presumably belonging to a single person were 'eyeballed' (checking every case manually) to filter out administrative twins by checking domicile, initials and apparent inconsistencies in clinical history.
Study parameters
Response rate in PROHTECT was operationally defined as the proportion of eligible women of both arms who sent in an informed consent form, combined with submission of a selfsampled specimen for women assigned to the self-sampling group. 6, 7 hrHPV prevalence was defined as percentage of women with HC2 hrHPV-positive self-sampled specimens. 6, 7 Yields of PCIN2/PCIN3/cervical carcinoma refer to the 18-month cumulative yields of these lesions in women in the self-sampling group who submitted a self-collected specimen or women who participated in the screening programme.
Ethnic status of non-attendees defined by country of birth was retrieved from the invitational database of the Regional Health Council. In accordance with the method of the Dutch Central Bureau of Statistics, countries of origin (in total, n = 188) were grouped into three major groups: The Netherlands (native Dutch), Other Developed countries (i.e. Europe, United States of America/Canada, Australia and New-Zealand) and Developing countries (i.e. the major four immigrant populations in the Netherlands (The Netherlands Antilles, Surinam, Turkey and Morocco) and Other Developing countries).
In the Netherlands, women are invited for screening every five years in the year in which they reach the age of 30, 35, 40 etc. till 60 years. Age categorisation was based on the number of prior screening rounds for which women had been invited. As a consequence the following age categories were defined: 29-33 years, 34-38 years, 39-43 years, 44-48 years, 49-53 years, 54-58 years and 59-63 years.
For cytology screening history of non-attendees the time period between the invitation for HPV self-sampling and the last smear taken prior to the PROHTECT test was considered. For this subgroup comparison, only women who had been invited in one or more previous screening rounds (i.e. women aged 34-63 years; n = 43,979) were included since younger women had no screening history. Since the PALGA database was linked with the invitational database for call and recall not earlier than in 2006, smears made for the invitational screening programme and opportunistic/diagnostic smears were similarly assigned. Based on time since the last smear, women were categorised into one of three subgroups: 1. last smear taken 67 years before participating in HPV self-sampling, considered to represent women screened in the previous round, 2. last smear taken >7 years ago (i.e. underscreened women) or 3. no smear in the past (i.e. never screened women). It should be noticed that PALGA has been virtually complete only since 1990 onwards (www.palga.nl). This means that the screening history can be screened only till 1990, and 'no screening history in the past' is defined as no screening history in the past approximately 15 years.
Data analysis
The pooled 18-month cumulative PCIN2/PCIN3 yields in self-sampling responders were compared with those of screening responders using Mantel-Haenszel (M-H) Chisquare testing. For analysing the age stratified data we used the M-H test of homogeneity. We performed multiple logistic regression analyses models on the potential risk factors as ethnic background, age group and screening history. Outcome measures were response to HPV self-sampling invitation, hrHPV test result and PCIN2/PCIN3/carcinoma. In the analyses for response to self-sampling invitation, the method of invitation (selfsampling or second recall) was also included as a predictor. Significance of the effects was evaluated with the Wald test. For all tests a significance level (a) of 0AE05 was used.
The analyses were performed by using SPSS 15AE0 software and STATA 10AE0 package)
Results

HPV self-sampling responders of non-attendees of the regular screening programme
In the PROHTECT studies, a total of 54,482 non-attendees were recruited, of whom 53,937 women were allocated to the self-sampling group and 545 to the recall control group. A total of 1490 women were non-eligible, mainly due to previous hysterectomy, leaving 52,447 women in the self-sampling group. Seven women in the recall control group were non-eligible, leaving 538 women. Finally 15,274 women (29%) submitted a self-sampled specimen. Table 1 provides further details of the self-sampling groups of the individual PROHTECT studies.
3.2.
Comparison of PCIN2/PCIN3 yields between selfsampling responders and screening participants Table 2 show the pooled cumulative 18-month PCIN2/PCIN3 yields in PROHTECT self-sampling responders versus screening participants. The PCIN2/PCIN3 yields of self-sampling responders were higher than those of screening participants (PCIN2: relative risk (RR) = 1.6, 95% confidence interval = 1.4-1.9; PCIN3: RR = 1.8, 95% CI = 1.5-2.1). These relative risk values increased with age (test of homogeneity (M-H): PCIN2: p = 0.04; PCIN3: p = 0.03), but were also significantly higher than 1 in women aged 29-33 years (PCIN2: RR = 1.4, 95% CI=1.1-1.8; PCIN3: RR = 1.6, 95% CI = 1.2-2.2). When restricting the analysis to women who had abnormal cytology (PBMD) at baseline similar relative risk values were obtained. In for example women aged 29-33 years with abnormal cytology these relative risks were 1.4 (95% CI = 1.1-1.8) and 1.6 (95% CI = 1.2-2.1) for PCIN2 and PCIN3, respectively.
Also cervical carcinomas were more frequently found amongst self-sampling responders than regular screening participants (0.09% versus 0.03%, p = 0.002; Table 2 ). Due to the low number of carcinomas the effect of age could not be tested.
3.3.
Response rate of non-attendees in relation to invitational method, ethnicity, age, and screening history
The response rate was analysed by fitting a logistic regression model with method of invitation, ethnicity, age group and screening history as predictors.
Women assigned to the self-sampling group responded significantly better than those assigned to the recall control group (29% versus 12%; v 2 (1) = 73.9, p < 0.001, Odds Ratio (OR) = 3.2, 95% CI = 2.5-4.2; Table 2 ). The response rate was also related to ethnicity (v (Table 3) .
There was no age trend in the response rate amongst PROH-TECT-women (Table 4) . Amongst women of P34 years, those who were screened at the previous screening round revealed a higher response rate (7259/21, 185; 34%) than underscreened or never screened women (5733/23,240; 25%; v 2 (1) = 389.4, p < 0AE001, OR = 1.5, 95% CI = 1.5-1.6). This difference was also evident when the analysis was restricted to women P39 years, who had been invited at least to two prior screening rounds (v 2 (1) = 420.9, p < 0.001, OR = 2.7, 95% CI = 2.5-3.0). Strikingly, amongst women P39 years, never screened women revealed a higher response rate (2270/9151; 25%) than underscreened women (2039/9024; 23%; v 2 (1) = 33.3, p < 0.001, OR = 1.2, 95% CI = 1.2-1.3). This was evident for women of all ethnic groups, although for immigrant women from Other Developing countries this difference did not reach significance (Fig. 2) 
3.4.
HPV prevalence in relation to ethnicity, age, and screening history (Table 4) .
3.5.
PCIN2/PCIN3 yield in relation to ethnicity, age, and screening history Sixty one (0.4%) of the self-sampling responders had CIN2, 144 (0.9%) CIN3 and 13 (0.09%) had cervical carcinoma. 1 The overall PCIN2 and PCIN3 yields were 1.4% (n = 218) and 1AE0% (n = 157), respectively (Table 3) . Both the PCIN2 and PCIN3 rates were related to ethnicity (PCIN2: v (1) = 8.7, p < 0.01, OR = 2.6, 95% CI = 1.4-4.9). No significant difference was found between immigrant women from Developed countries and those from Developing countries. Due to the low frequencies of PCIN2 no further subdivision was made amongst women from Developing countries.
The PCIN2/PCIN3 yields were significantly related to age (PCIN2: v 2 (6) = 52.3, p < 0.001; PCIN3: v 2 (6) = 38.4, p < 0.001) and were relatively high in young women. Of all PCIN2 lesions, 32% were in the group of 29-33 years and only 3.2% were in the group of 59-63 years; likewise 34% of all PCIN3 were in the group of 29-33 years and 3.8% in women of 59-63 years.
The effect of screening history of women P34 years on PCIN2/PCIN3/carcinoma yields, stratified by ethnicity and age, is shown in Table 5 . There was a significant effect of screening history on both PCIN2 (v 2 (2) = 11.1, p < 0.01) and PCIN3 (v 2 (2) = 6.6, p < 0.05). Women who were under-or never screened revealed significantly higher PCIN2/PCIN3 yields than women screened within the last 7 years (PCIN2: v The PCIN2/PCIN3 yields were highest in never screened women (Fig. 3) .
Both in women of P34 and those of P39 years there was no significant effect of screening history on carcinoma yield. This reflects the fact that two carcinomas were diagnosed in women 633 years and the number of carcinomas in the older age groups was apparently too low to reach significance.
Discussion
In the screening region of the Netherlands investigated here the attendance rate was 67%, which is in agreement with the overall attendance in the Netherlands after one year (65%). 17 Together with opportunistic smears the coverage of the population after 5 years is about 77%, 7-19 which leaves 23% invited women unprotected. We showed that the yields of PCIN2/PCIN3 were higher in the HPV self-sampling group of the non-attendees than in the regular attendees of the screening programme. Moreover, the relative PCIN2/PCIN3 risk values increased with age. In addition, we found that Dutch non-attendees responded better and also revealed significantly higher PCIN2/PCIN3 yields than their immigrant counterparts. Amongst women invited at earlier screening rounds, never screened women responded better to HPV self-sampling than underscreened women, independent from ethnicity. These underscreened and never screened women displayed the highest risk of PCIN2/PCIN3/carcinoma. These are the women who health programme managers particularly like to target to improve cervical cancer prevention strategies, supporting the notion that offering HPV self-sampling is a meaningful and effective approach for reaching those women who are in the highest need for cervical screening. Since non-attendees harbour more than 50% of cervical cancers, 9, 12 targeting of approximately 30% of these women by HPV selfsampling is likely to result in earlier detection of at least 15% of the cervical carcinomas.
For this study, we pooled data from two large self-sampling studies. Independent from ethnicity, age, and screening history, we measured different response rates between the individual PROHTECT studies. In PROHTECT-1 slightly fewer women responded than in PROHTECT-2 (27% versus 31%). This small difference may partly reflect a higher acceptability of the brush device used in PROHTECT-2 compared to the lavage-device used in PROHTECT-1. Alternatively, since PROHTECT-1 was performed prior to PROHTECT-2, the difference might be attributable to more awareness, and therefore less uncertainty, due to the earlier publicity around the PROHTECT-1 study.
Most interesting is the finding that never screened women were more likely to respond than underscreened women, independent from the ethnic background. Although it is still unclear why never screened women responded better than underscreened women, a plausible explanation might be that these women consistently refuse to visit the physician for making a preventive smear because of cultural, religious and/or organisational reasons. HPV self-sampling may help to overcome this barrier.
It should be realised that increased PCIN2/PCIN3 yield in self-sampling responders might be the result of a more sensitive screening test (hrHPV test used in self-sampling compared to the cytology test used for screening participants). However, similar relative risk values were obtained after restricting the analysis to women with abnormal cytology at baseline. Therefore, the increased relative risk of selfsampling responders cannot solely be attributed to a more sensitive screening test.
An unexpected observation was that an increased relative risk of PCIN2/PCIN3 was also found amongst self-sampling responders for whom it was their first screening round. A likely explanation for this finding is that women at risk because of their lifestyle (e.g. in terms of sexual behaviour and smoking habits) are better targeted by offering HPV self-sampling than by invitation for a physician-collected cervical scrape. The increased relative risks by age most likely reflect an overall poorer screening history of older self-sampling responders.
Our study is unique, because of its large size and performance within the setting of the regular cervical screening programme. Moreover characteristics of non-attendees of the screening programme who responded to self-sampling for HPV testing has not been described before. A limitation is that we pooled two studies in which different collection devices were used. As reported earlier, 7 hrHPV-positivity rates slightly differed between samples collected by both devices, but the concordance between hrHPV-positivity rates in both types of self-collected samples and corresponding physician-collected cervical samples was very high (over 90%) in women with PCIN2. 6, 20 Furthermore, PCIN2 yield was comparable in both studies 7 indicating that it is unlikely that pooling the PROHTECT studies would influence the interpretation of the results.
Another limitation is that we did not test the prevalence of PCIN2 in women with hrHPV-negative self-sample test. The medical ethics committee considered follow-up of these women in light of the very high negative predictive value of the hrHPV test for PCIN2 an unnecessary burden. 21 Finally we defined ethnic status based on the country of birth. Thus some women from ethnic minorities who were born in the Netherlands might have been classified as 'native Dutch', even though culturally they may to some degree resemble paternal immigrant communities. Although this might play a role predominantly amongst younger women we think that the number of women concerned is limited. Most women who united with their husband by immigration in The Netherlands did so in the late 1970s and beginning of 1980s. The number of women born from these immigrated women and invited for screening (30-60 years) constitutes in our opinion therefore a small minority.
Finally, it is important to note that in order to make HPV self-sampling a successful alternative to physician-sampling, the whole organisation should be well controlled. This involves the sequence of sending the invitation with the selfsampling kit, return sending by surface mail, hrHPV testing with a clinically validated test that is compatible with the self-sampling device, follow-up of hrHPV-positive women by triage cytology by a physician and follow-up of hrHPV-positive women with normal cytology after 6 months to 1 year. We showed earlier that compliance to direct cytology triage is high (P90%) but that there is poor adherence to follow-up testing after 1 year (60%), which needs careful attention. 6, 7 Still, these results strongly argue to implement hrHPV testing on self-sampled material as an alternative for hrHPV testing on a physician taken scrape.
Conclusion
Amongst women who had not been screened in the previous screening round, those who were never screened before were preferentially attained when offering HPV self-sampling. This likely contributed to higher PCIN2/PCIN3 yields than found in regular screening participants, which is highly relevant for the success of the screening programme. Although native Dutch women responded better than immigrants, the response rates amongst immigrants from different countries hardly differed, making the method successful independent of the country of birth.
